Nilotinib Teva

Italy
Brand name Nilotinib Teva
Form capsules, hard gelatin
Active substance / Dosage
Prescription type Restricted prescription – non-repeatable, dispensable on hospital or specialist prescription
ATC code
Registration number 051303
Nilotinib Teva capsules, hard gelatin

PACKAGE LEAFLET

Package leaflet: information for the user

Nilotinib Teva 150 mg hard capsules, 200 mg hard capsules

nilotinib
Generic medicine
Please read this leaflet carefully before taking this medicine because it contains
important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not give it to other people, even if they have the same symptoms as you, because it may be harmful.
  • If you experience any side effects, including those not listed in this leaflet, contact your doctor or pharmacist. See section 4.

Contents of this leaflet:

  1. What Nilotinib Teva is and what it is used for
  2. What you need to know before taking Nilotinib Teva
  3. How to take Nilotinib Teva
  4. Possible side effects
  5. How to store Nilotinib Teva
  6. Contents of the pack and other information

1. What Nilotinib Teva is and what it is used for

What Nilotinib Teva is
Nilotinib Teva is a medicine containing an active substance called nilotinib.
What Nilotinib Teva is used for
Nilotinib Teva is used to treat a type of leukaemia called Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML). CML is a blood cancer that causes the body to produce too many abnormal white blood cells.
Nilotinib Teva is used in adult and paediatric patients with newly diagnosed CML or in patients with CML who no longer benefit from prior therapies, including imatinib. It is also used in adult and paediatric patients who have experienced severe adverse reactions to prior treatments and are no longer able to continue them.
How Nilotinib Teva works
In patients with CML, a change in DNA (genetic material) triggers a signal that causes the body to produce abnormal white blood cells. Nilotinib Teva blocks this signal, thereby stopping the production of these cells.
Monitoring during treatment with Nilotinib Teva
Regular check-ups, including blood tests, will be performed during treatment. These tests will monitor:

  • blood cell counts (white blood cells, red blood cells and platelets) to assess how well Nilotinib Teva is tolerated.
  • pancreatic and liver function to assess how well Nilotinib Teva is tolerated.
  • electrolyte levels in the body (potassium, magnesium). These electrolytes are important for heart function.
  • blood sugar and fat (lipid) levels.

Heart rate will also be monitored using a device that measures the heart's electrical activity (a test called an "ECG").
Your doctor will regularly evaluate your treatment and decide whether you should continue taking Nilotinib Teva. If you are told to stop taking this medicine, your doctor will continue to monitor your CML and may advise you to restart Nilotinib Teva if your condition indicates that this is necessary.
If you have any questions about how Nilotinib Teva works or why it has been prescribed for you or your child, please consult your doctor.

2. What you should know before taking Nilotinib Teva

Follow carefully all your doctor’s instructions. These instructions may differ from the
general information contained in this leaflet.
Do not take Nilotinib Teva

  • if you are allergic to nilotinib or to any of the other ingredients of this medicine (listed in section 6).
  • if you think you may be allergic, inform your doctor before taking Nilotinib Teva.

Warnings and precautions
Talk to your doctor or pharmacist before taking Nilotinib Teva:

  • if you have had previous cardiovascular events such as heart attack, chest pain (angina), problems with blood flow to the brain (stroke), or problems with blood flow to the leg (claudication), or if you have risk factors for cardiovascular disease such as high blood pressure (hypertension), diabetes, or problems with blood lipid levels (dyslipidemia).
  • if you have heart problems, such as an abnormal electrical signal called “QT interval prolongation”.
  • if you are being treated with medicines that lower your blood cholesterol (statins), affect heart rhythm (antiarrhythmics), or affect the liver (see Other medicines and Nilotinib Teva).
  • if you have low levels of potassium or magnesium.
  • if you have liver or pancreatic disorders.
  • if you have symptoms such as tendency to bruising, feeling tired, shortness of breath, or have had repeated infections.
  • if you have had surgery involving removal of the entire stomach (total gastrectomy).
  • if you have ever had or may currently have hepatitis B infection. This is because Nilotinib Teva may cause reactivation of hepatitis B, which in some cases can be fatal. Your doctor will closely monitor you for signs of this infection before starting treatment. If any of these conditions apply to you or your child, inform your doctor.

During treatment with Nilotinib Teva

  • if you faint (lose consciousness) or experience an irregular heartbeat while taking this medicine, inform your doctor immediately, as this may be a sign of a serious heart condition. Prolongation of the QT interval or an irregular heartbeat may lead to sudden death. Uncommon cases of sudden death have been reported in patients treated with nilotinib.
  • if you experience sudden palpitations, severe muscle weakness or paralysis, seizures, or sudden changes in thinking or alertness, inform your doctor immediately, as these may be signs of a rapid breakdown of tumor cells called tumor lysis syndrome. Rare cases of tumor lysis syndrome have been reported in patients treated with nilotinib.
  • if you experience chest pain or discomfort, numbness or weakness, difficulty walking or speaking, or pain, color change, or cold sensation in a limb, inform your doctor immediately, as these may be signs of a cardiovascular event. Serious cardiovascular events, including problems with blood flow to the leg (peripheral arterial occlusive disease), ischemic heart disease, and problems with blood flow to the brain (ischemic cerebrovascular disease), have been reported in patients treated with nilotinib. Your doctor should assess your blood lipid (fat) and blood sugar levels before starting treatment with Nilotinib Teva and during treatment.
  • if you experience swelling of the feet or hands, generalized swelling, or rapid weight gain, inform your doctor, as these may be signs of severe fluid retention. Uncommon cases of severe fluid retention have been reported in patients treated with nilotinib. If you are the parent of a child being treated with Nilotinib Teva, inform your doctor if any of the above conditions apply to your child.

Children and adolescents
Nilotinib Teva is a treatment for children and adolescents with CML. There is no experience with the use of
this medicine in children under 2 years of age. There is no experience with the use of Nilotinib
Teva in children under 10 years of age with newly diagnosed disease, and limited experience in patients under 6 years of age who no longer benefit from prior CML treatment.
Some children and adolescents taking Nilotinib Teva may experience slower than normal growth. Your doctor will monitor growth with regular check-ups.
Other medicines and Nilotinib Teva
Nilotinib Teva can interact with other medicines.
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicine. This includes in particular:

  • antiarrhythmics – used to treat irregular heartbeat;
  • chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin – medicines that may have an undesirable effect on the heart’s electrical activity;
  • ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin – used to treat infections;
  • ritonavir – a medicine of the “protease inhibitor” class used to treat HIV;
  • carbamazepine, phenobarbital, phenytoin – used to treat epilepsy;
  • rifampicin – used to treat tuberculosis;
  • St. John’s wort – a herbal product used to treat depression and other conditions (also known as Hypericum perforatum);
  • midazolam – used to relieve anxiety before surgery;
  • alfentanil and fentanyl – used to treat pain and as sedatives before or during surgery or medical procedures;
  • cyclosporine, sirolimus, and tacrolimus – medicines that suppress the body’s ability to “defend itself” and fight infections, commonly used to prevent rejection of transplanted organs such as liver, heart, and kidneys;
  • dihydroergotamine and ergotamine – used to treat dementia;
  • lovastatin, simvastatin – used to treat high blood lipid levels;
  • warfarin – used to treat blood clotting disorders (such as blood clots or thrombosis);
  • astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, or ergot alkaloids (ergotamine, dihydroergotamine).

These medicines should be avoided during treatment with Nilotinib Teva. If you are taking
any of these medicines, your doctor may prescribe alternative treatments.
If you are taking a statin (a medicine that lowers your blood cholesterol), talk to your
doctor or pharmacist. When taken with certain statins, Nilotinib Teva may increase the risk of statin-related muscle problems, which in rare cases may lead to severe muscle damage (rhabdomyolysis) and subsequent kidney damage.
Also, inform your doctor or pharmacist before taking Nilotinib Teva if you are taking any
antacid, i.e., a medicine for heartburn. These medicines must be taken separately from Nilotinib Teva:

  • H2 blockers, which reduce acid production in the stomach. H2 blockers should be taken approximately 10 hours before and approximately 2 hours after taking Nilotinib Teva;
  • antacids such as those containing aluminium hydroxide, magnesium hydroxide, and simeticone, which neutralize high stomach acidity. These antacids should be taken approximately 2 hours before or approximately 2 hours after taking Nilotinib Teva.

You should also inform your doctor if you are already taking Nilotinib Teva and have been prescribed a new
medicine not previously taken during treatment with Nilotinib Teva.
Nilotinib Teva with food and drinks
Do not take Nilotinib Teva with food. Food can increase the absorption of Nilotinib Teva and
thus increase the amount of Nilotinib Teva in the blood to a dangerous level. Do not drink
grapefruit juice or eat grapefruit. It may increase the amount of Nilotinib Teva in the blood to
a dangerous level.
Pregnancy and breastfeeding

  • Nilotinib Teva is not recommended during pregnancy unless strictly necessary. If you are pregnant or think you may be pregnant, inform your doctor, who will discuss with you whether you can take this medicine during pregnancy.
  • Women who may become pregnant are advised to use a highly effective method of contraception during treatment and for two weeks after stopping treatment.
  • Breastfeeding is not recommended during treatment with Nilotinib Teva and for two weeks after the last dose. Inform your doctor if you are breastfeeding. If you are pregnant, suspect you may be pregnant, plan to become pregnant, or are breastfeeding, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
If you experience side effects (such as dizziness or vision problems) that may affect your ability to drive safely or operate tools or machinery after taking
this medicine, you should stop such activities until the effect has disappeared.
Nilotinib Teva contains lactose
This medicine contains lactose (also known as milk sugar). If your doctor has diagnosed you with an intolerance to certain sugars, contact your doctor before taking this medicine.
Nilotinib Teva 50 mg and 150 mg contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per dose, i.e., essentially ‘sodium-free’.

3. How to take Nilotinib Teva

Take this medicine exactly as instructed by your doctor or pharmacist. If you have any doubts, consult your doctor or pharmacist.

How much Nilotinib Teva to take

Use in adults

  • Patients with newly diagnosed CML: The recommended dose is 600 mg daily. This dose is achieved by taking two 150 mg hard capsules twice daily.
  • Patients who are no longer benefiting from prior CML treatment: The recommended dose is 800 mg daily. This dose is achieved by taking two 200 mg hard capsules twice daily.

Use in children and adolescents

  • The dose given to your child will depend on the child's weight and height. Your doctor will calculate the correct dose to use and will tell you which capsules and how many capsules of Nilotinib Teva should be given to your child. The total daily dose administered to your child must not exceed 800 mg.

Your doctor may prescribe a lower dose depending on how you respond to treatment.

Elderly people (65 years and older)
Nilotinib Teva may be used in people aged 65 years and older at the same dose as for other adults.

When to take Nilotinib Teva
Take the hard capsules:

  • twice daily (approximately every 12 hours);
  • at least 2 hours after eating;
  • and then wait 1 hour before eating again.
    If you have any questions about when to take this medicine, speak with your doctor or pharmacist. Taking Nilotinib Teva at the same time each day will help you remember when to take the capsules.

How to take Nilotinib Teva

  • Swallow the hard capsules whole with water.
  • Do not take food together with the hard capsules.
  • Do not open the hard capsules. If you or your child cannot swallow the capsule whole, another medicine containing nilotinib should be used instead of Nilotinib Teva.

How long to take Nilotinib Teva
Continue taking Nilotinib Teva every day for as long as your doctor has prescribed it. This is a long-term treatment. Your doctor will monitor your condition regularly to check that the treatment is having the desired effect.
Your doctor may consider stopping treatment with Nilotinib Teva based on specific criteria.
If you have any questions about how long to take Nilotinib Teva, speak with your doctor.

If you take more Nilotinib Teva than you should
If you have taken more Nilotinib Teva than you should, or if someone else has accidentally taken your hard capsules, contact a doctor or hospital immediately for advice. Show them the packaging of the capsules and this patient information leaflet. Medical treatment may be necessary.

If you forget to take Nilotinib Teva
If you forget to take a dose, take the next dose as scheduled. Do not take a double dose to make up for the forgotten capsule.

If you stop taking Nilotinib Teva
Do not stop treatment with this medicine unless your doctor tells you to. Stopping Nilotinib Teva without your doctor's recommendation puts you at risk of worsening of your disease, which could be life-threatening. Make sure to discuss with your doctor, nurse, and/or pharmacist if you are considering stopping Nilotinib Teva.

If your doctor recommends stopping treatment with Nilotinib Teva
Your doctor will regularly assess your treatment with a specific diagnostic test and decide whether you should continue taking this medicine. If you are told to stop taking Nilotinib Teva, your doctor will continue to monitor your CML carefully before, during, and after stopping Nilotinib Teva, and may instruct you to restart Nilotinib Teva if your condition indicates that it is necessary.

If you have any doubts about using this medicine, consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and usually disappear after a period of treatment ranging from a few days to a few weeks.
Some side effects can be serious.

  • signs of musculoskeletal pain: joint and muscle pain
  • signs of heart problems: chest pain or discomfort, high or low blood pressure, irregular heartbeat (fast or slow), palpitations (sensation of rapid heartbeat), fainting, bluish discoloration of lips, tongue or skin
  • signs of arterial blockage: pain, discomfort, weakness or cramps in the leg muscles, which may be due to reduced blood flow, leg or arm ulcers that do not heal or heal slowly, and noticeable changes in color (bluish or pale) or temperature (coldness) of the affected leg, arm, toes or hands
  • signs of underactive thyroid gland: weight gain, fatigue, hair loss, muscle weakness, feeling cold
  • signs of overactive thyroid gland: fast heartbeat, protruding eyes, weight loss, swelling in the front of the neck
  • signs of kidney or urinary tract problems: thirst, dry skin, irritability, dark urine, reduced urine output, difficulty or pain when urinating, urgent need to urinate, blood in urine, abnormal urine color
  • signs of high blood sugar levels: excessive thirst, increased urine output, increased appetite with weight loss, fatigue
  • signs of dizziness: dizziness or spinning sensation
  • signs of pancreatitis: severe upper abdominal pain (in the center or left side)
  • signs of skin problems: painful red nodules, skin pain, skin redness, peeling or blisters
  • signs of fluid retention: rapid weight gain, swelling in hands, ankles, feet or face
  • signs of migraine: severe headache often accompanied by nausea, vomiting and sensitivity to light
  • signs of blood disorders: fever, tendency to bruise or unexplained bleeding, severe or frequent infections, unexplained weakness
  • signs of venous thrombosis: swelling and pain in part of the body
  • signs of nervous system disorders: weakness or paralysis of limbs or face, difficulty speaking, severe headache, seeing, hearing or sensing things that are not there, changes in vision, loss of consciousness, confusion, disorientation, tremors, tingling, pain or numbness in fingers or toes
  • signs of lung problems: difficulty breathing or painful breathing, cough, wheezing with or without fever, swelling in feet or legs
  • signs of gastrointestinal disorders: abdominal pain, nausea, vomiting blood, black or bloody stools, constipation, heartburn, gastric reflux, bloated abdomen
  • signs of liver problems: yellowing of the skin and eyes, nausea, loss of appetite, dark urine
  • signs of liver infection: recurrence (reactivation of hepatitis B infection)
  • signs of eye problems: vision disturbances including blurred vision, double vision or perception of flashes of light, decreased visual acuity or vision loss, blood in the eye, increased sensitivity of the eyes to light, eye pain, redness, itching or irritation, dry eyes, eyelid swelling or itching
  • signs of electrolyte imbalance: nausea, shortness of breath, irregular heartbeat, cloudy urine, fatigue and/or joint problems associated with abnormal blood test results (such as high levels of potassium, uric acid and phosphorus and low levels of calcium)
    Contact your doctor immediately if you notice any of the side effects listed above.

Some side effects are very common (may affect more than 1 in 10 people)

  • diarrhea
  • headache
  • lack of energy
  • muscle pain
  • itching, rash
  • nausea
  • constipation
  • vomiting
  • hair loss
  • limb pain, bone pain and spinal pain after stopping treatment with Nilotinib Teva
  • slowed growth in children and adolescents
  • upper respiratory tract infection including sore throat, runny or stuffy nose, sneezing
  • low levels of blood cells (red blood cells, platelets) or hemoglobin
  • high level of lipase in blood (pancreatic function)
  • high level of bilirubin in blood (liver function)
  • high level of alanine aminotransferase in blood (liver enzymes)

Some side effects are common (may affect up to 1 in 10 people)

  • pneumonia
  • abdominal pain, stomach discomfort after meals, gas, bloating or abdominal distension
  • bone pain, muscle spasms
  • pain (including neck pain)
  • dry skin, acne, decreased skin sensitivity
  • weight loss or weight gain
  • insomnia, depression, anxiety
  • night sweats, excessive sweating
  • general feeling of being unwell
  • nosebleeds
  • signs of gout: painful and swollen joints
  • inability to achieve or maintain an erection
  • flu-like symptoms
  • sore throat
  • bronchitis
  • ear pain, hearing noises (e.g. ringing, buzzing) in the ears with no external source (also called tinnitus)
  • hemorrhoids
  • heavy menstrual periods
  • itching of hair follicles
  • oral or vaginal candidiasis
  • signs of conjunctivitis: eye discharge with itching, redness and swelling
  • eye irritation, red eyes
  • signs of hypertension: high blood pressure, headache, dizziness
  • flushing
  • signs of occlusive peripheral arterial disease: pain, discomfort, weakness or cramps in leg muscles, which may be due to reduced blood flow, leg or arm ulcers that do not heal or heal slowly, and noticeable changes in color (bluish or pale) or temperature (coldness) of legs or arms (possible signs of arterial blockage in leg, arm, toes or hands)
  • shortness of breath (also called dyspnea)
  • mouth ulcers with inflamed gums (also called stomatitis)
  • high level of amylase in blood (pancreatic function)
  • high level of creatinine in blood (kidney function)
  • high level of alkaline phosphatase or creatine phosphokinase in blood
  • high level of aspartate aminotransferase in blood (liver enzymes)
  • high level of gamma-glutamyl transferase in blood (liver enzymes)
  • signs of leucopenia or neutropenia: low white blood cell count
  • increased number of platelets or white blood cells in blood
  • low blood levels of magnesium, potassium, sodium, calcium or phosphorus
  • increased blood levels of potassium, calcium and phosphorus
  • high levels of fats (including cholesterol) in blood
  • high level of uric acid in blood

Some side effects are uncommon (may affect up to 1 in 100 people)

  • allergy (hypersensitivity to Nilotinib Teva)
  • dry mouth
  • breast pain
  • flank pain or discomfort
  • increased appetite
  • breast enlargement in men
  • herpes virus infection
  • stiffness of muscles and joints, joint swelling
  • sensation of body temperature changes (including feeling hot or cold)
  • taste disturbance
  • frequent urge to urinate
  • signs of gastric mucosal inflammation: abdominal pain, nausea, vomiting, diarrhea, abdominal distension
  • memory loss
  • skin cysts, skin thinning or thickening, thickening of the outer skin layer, skin color changes
  • signs of psoriasis: thickened red/silvery skin patches
  • increased skin sensitivity to light
  • hearing difficulty
  • joint inflammation
  • urinary incontinence
  • intestinal inflammation (also called enterocolitis)
  • anal abscess
  • nipple swelling
  • symptoms of restless legs syndrome (an irresistible urge to move part of the body, usually legs, associated with discomfort)
  • signs of sepsis: fever, chest pain, elevated/increased heart rate, shortness of breath or rapid breathing
  • skin infection (subcutaneous abscess)
  • skin wart
  • increased levels of specific types of white blood cells (called eosinophils) in blood
  • signs of lymphopenia: low white blood cell count
  • high level of parathyroid hormone in blood (a hormone regulating calcium and phosphorus levels)
  • high level of lactate dehydrogenase in blood (an enzyme)
  • signs of low blood sugar: nausea, sweating, weakness, dizziness, tremor, headache
  • dehydration
  • abnormal blood fat levels
  • involuntary tremor (also called tremor)
  • difficulty concentrating
  • unpleasant or abnormal sensation to touch (also called dysesthesia)
  • fatigue (also called tiredness)
  • numbness or tingling in fingers or toes (also called peripheral neuropathy)
  • facial muscle paralysis
  • red spot in the white of the eye due to broken blood vessels (also called conjunctival hemorrhage)
  • blood in the eyes (also called eye hemorrhage)
  • eye irritation
  • signs of heart attack (also called myocardial infarction): sudden crushing chest pain, fatigue, irregular heartbeat
  • signs of heart murmur: fatigue, chest discomfort, dizziness, chest pain, palpitations
  • fungal foot infection
  • signs of heart failure: shortness of breath, difficulty breathing when lying down, swelling of feet or legs
  • pain behind the breastbone (also called pericarditis)
  • signs of hypertensive crisis: severe headache, dizziness, nausea
  • leg pain and weakness when walking (also called intermittent claudication)
  • signs of narrowing of arteries in limbs: possible high blood pressure, painful cramps in one or both hips, thighs or calves after physical activity such as walking or climbing stairs, numbness or weakness in legs
  • bruising (when you have not injured yourself)
  • fat deposits in arteries that may cause blockage (also called atherosclerosis)
  • signs of low blood pressure (also called hypotension): dizziness, lightheadedness or fainting
  • signs of pulmonary edema: shortness of breath
  • signs of pleural effusion: fluid buildup between the layers of tissue lining the lungs and chest cavity (which, if severe, may reduce the heart's ability to pump blood), chest pain, cough, hiccups, rapid breathing
  • signs of interstitial lung disease: cough, difficulty breathing, painful breathing
  • signs of pleural pain: chest pain
  • signs of pleuritis: cough, painful breathing
  • hoarseness
  • signs of pulmonary hypertension: high blood pressure in the lung arteries
  • wheezing
  • sensitive teeth
  • signs of gum inflammation (also called gingivitis): bleeding gums, tender or swollen gums
  • high level of urea in blood (kidney function)
  • changes in blood proteins (low globulin levels or presence of paraprotein)
  • high level of unconjugated bilirubin in blood
  • high level of troponin in blood

Some side effects are rare (may affect up to 1 in 1,000 people)

  • redness and/or swelling and possible peeling of palms and soles (so-called hand-foot syndrome)
  • mouth warts
  • sensation of breast hardness or stiffness
  • thyroid inflammation (also called thyroiditis)
  • disturbed or depressed mood
  • signs of secondary hyperparathyroidism: bone and joint pain, excessive urination, abdominal pain, weakness, fatigue
  • signs of narrowing of arteries in the brain: partial or complete vision loss in both eyes, double vision, vertigo (dizziness), numbness or tingling, loss of coordination, dizziness or confusion
  • brain swelling (possible headache and/or mental status changes)
  • signs of optic neuritis: blurred vision, vision loss
  • signs of cardiac dysfunction (reduced ejection fraction): fatigue, chest discomfort, dizziness, pain, palpitations
  • low or high insulin levels in blood (a hormone regulating blood sugar levels)
  • low level of insulin C-peptide in blood (pancreatic function)
  • sudden death

The following other side effects have been reported with unknown frequency (cannot be estimated from the available data):

  • signs of cardiac dysfunction (ventricular dysfunction): shortness of breath, exertion at rest, irregular heartbeat, chest discomfort, dizziness, pain, palpitations, excessive urination, swelling in feet, ankles and abdomen.

Reporting of side effects
If you experience any side effect, including those not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Nilotinib Teva

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date stated on the carton and blister after "Exp". The expiry date refers to the last day of that month.
  • This medicine does not require any special storage conditions.
  • Do not use this medicine if you notice that the packaging is damaged or tampered with.
  • Do not dispose of any medicine via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Package contents and other information

What Nilotinib Teva contains

  • The active substance is nilotinib.

Each 150 mg hard capsule contains 150 mg of nilotinib (as dihydrochloride).
The other components are:
Capsule contents: monohydrate lactose, crospovidone type A (E1202), anhydrous colloidal silica (E551), magnesium stearate (E470b)
Capsule shell: hypromellose (E464), purified water, carrageenan (E407), potassium chloride (E508), erythrosine (E127), yellow iron oxide (E172), red iron oxide (E172), titanium dioxide (E171)
Printing ink: shellac (E904), propylene glycol (E1520), potassium hydroxide (E525), black iron oxide (E172)
See section 2, “Nilotinib Teva contains lactose and sodium”.

Each 200 mg hard capsule contains 200 mg of nilotinib (as dihydrochloride).
The other components are:
Capsule contents: monohydrate lactose, crospovidone type A (E1202), anhydrous colloidal silica (E551), magnesium stearate (E470b)
Capsule shell: hypromellose (E464), purified water, carrageenan (E407), potassium chloride (E508), yellow iron oxide (E172), titanium dioxide (E171)
Printing ink: shellac (E904), propylene glycol (E1520), potassium hydroxide (E525), black iron oxide (E172)
See section 2, “Nilotinib Teva contains lactose”.

Description of the appearance of Nilotinib Teva and the contents of the pack

Nilotinib Teva 150 mg is presented as red, opaque, hard capsules of size 1 (approximately 19.3 mm in length), with a black horizontal marking “150 mg” on the body. The hard capsules contain a white to yellowish powder.

Nilotinib Teva 200 mg is presented as light yellow, opaque, hard capsules of size 0 (approximately 21.4 mm in length), with a black horizontal marking “200 mg” on the body. The hard capsules contain a white to yellowish powder.

Nilotinib Teva 150 mg hard capsules are packaged in PVC/PE/PVdC/Alu blisters or OPA/Alu/PVC/Alu blisters in:
Single packs containing 28, 30, 40 hard capsules and multiple packs containing 112 (4 packs of 28), 120 (3 packs of 40) and 392 (14 packs of 28) hard capsules.

Nilotinib Teva 150 mg hard capsules are also packaged in perforated, divisible unit-dose blisters in PVC/PE/PVdC/Alu or OPA/Alu/PVC/Alu in:
Single packs containing 28 x 1, 30 x 1, 40 x 1, 112 x 1 hard capsules and multiple packs containing 112 x 1 (4 packs of 28 x 1), 120 x 1 (3 packs of 40 x 1) and 392 x 1 (14 packs of 28 x 1) hard capsules.

Nilotinib Teva 200 mg hard capsules are packaged in PVC/PE/PVdC/Alu blisters or OPA/Alu/PVC/Alu blisters in:
Single packs containing 28, 30, 40 hard capsules and multiple packs containing 112 (4 packs of 28), 120 (3 packs of 40) and 392 (14 packs of 28) hard capsules.

Nilotinib Teva 200 mg hard capsules are also packaged in perforated, divisible unit-dose blisters in PVC/PE/PVdC/Alu or OPA/Alu/PVC/Alu in:
Single packs containing 28 x 1, 30 x 1, 40 x 1, 112 x 1 hard capsules and multiple packs containing 112 x 1 (4 packs of 28 x 1), 120 x 1 (3 packs of 40 x 1) and 392 x 1 (14 packs of 28 x 1) hard capsules.

Not all pack sizes may be marketed.

Marketing Authorization Holder
Teva Italia S.r.l. - Piazzale Luigi Cadorna, 4 - 20123 Milano

Manufacturer
PharOS MT Ltd.
HF62X, Hal Far Industrial Estate, Birzebbugia BBG3000
Malta

Pharos Pharmaceutical Oriented Services Ltd.
Lesvou Street End, Thesi Loggos, Industrial Zone, Metamorfossi, 144 52
Greece